In KRAS-driven lung cancer, the LKB1 mutation represses STING expression by increasing DNMT1 and EZH2 activity, which target the methylation and modification of the H3K27Me3 of the STING promoter, respectively.135 In triple-negative breast cancer, MYC could activate DNMT1 transcription and induce DNA methylation within the 5’-untranslated region of STING to suppress STNG expression.136 LncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) can also bind to DNMT1 and suppress STING for tumor evasion.137. Here, KRAS is linked to lung carcinoma.